BioLife Solutions, Inc. (BLFS) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $20.27. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of BLFS = $326.33 (+1509.9% from the current price, the stock appears undervalued). Analyst consensus target is BLFS = $33 (+62.8% upside).
Valuation: BLFS trades at a trailing Price-to-Earnings (P/E) of -79 (S&P 500 average ~25).
Financials: revenue is $96M, -12.3%/yr average growth. Net income is $12M (loss), growing at +54%/yr. Net profit margin is -12.6% (negative). Gross margin is 64.6% (+31.3 pp trend).
Balance sheet: total debt is $18M against $372M equity (Debt-to-Equity (D/E) ratio 0.05, conservative). Current ratio is 5.23 (strong liquidity). Debt-to-assets is 4.4%. Total assets: $406M.
Analyst outlook: 17 / 17 analysts rate BLFS as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 56/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).
